Strategic radiopharma Aptevo is actively expanding into radiopharmaceutical oncology programs through a 50/50 collaboration with Niowave, presenting a direct opportunity to engage with teams focused on radiopharmaceutical development, manufacturing, and regulatory pathways.

Leadership expansion Recent appointment of a new Chief Scientific Officer and a planned leadership transition to a President/CEO creates openings for high-level alliances, co-development discussions, and joint scientific advisory opportunities with external partners.

Platform leverage With the proprietary ADAPTIR and ADAPTIR-FLEX platforms driving immuno-oncology programs, there is potential to position solution selling around platform scalability, manufacturing partnerships, and cross-program collaboration for accelerate go-to-market timelines.

Financial runway A $60M equity line of credit alongside ongoing clinical-stage activities suggests a willingness to engage in strategic financing, partnerships, and milestone-driven collaborations to de-risk and fund multi-program portfolios.

Clinical pipeline Near-term programs like mipletamig and radiopharmaceutical initiatives targeting Nectin-4 indicate opportunities to discuss translational development services, specialized radiochemistry support, and clinical program consulting with sponsor-ready assets.